Numerous large-scale RCTs have demonstrated substantial beneficial effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter-2 inhibitors (SGLT-2is) on the risk of cardiovascular complications, such as myocardial infarction and stroke, heart failure, and the progression of CKD to end-stage renal disease (ESKD) and albuminuria [2]. The gene discussed is GLP1R; the disease is chronic kidney disease.